StockOtters
StockOttersSupply Chain Map

WuXi Biologics (Cayman) Inc.

WXXWY

Financial Statements

Income Statement (Annual)

Amounts in millions

2024

12/31/2024

Revenue
18,675
Cost of Revenue
11,025
Gross Profit
7,651
Gross Margin
41.0%
Operating Income
4,974
Operating Margin
26.6%
Net Income
3,356
Net Margin
18.0%
EPS (Basic)
$1.56
EPS (Diluted)
$1.56
EBITDA
6,429
EBITDA Margin
34.4%

2023

12/31/2023

Revenue
17,034
Cost of Revenue
10,206
Gross Profit
6,828
Gross Margin
40.1%
Operating Income
4,450
Operating Margin
26.1%
Net Income
3,400
Net Margin
20.0%
EPS (Basic)
$1.64
EPS (Diluted)
$1.54
EBITDA
5,502
EBITDA Margin
32.3%

2022

12/31/2022

Revenue
15,269
Cost of Revenue
8,545
Gross Profit
6,724
Gross Margin
44.0%
Operating Income
4,350
Operating Margin
28.5%
Net Income
4,420
Net Margin
29.0%
EPS (Basic)
$2.12
EPS (Diluted)
$2.02
EBITDA
5,069
EBITDA Margin
33.2%

2021

12/31/2021

Revenue
10,290
Cost of Revenue
5,461
Gross Profit
4,829
Gross Margin
46.9%
Operating Income
3,188
Operating Margin
31.0%
Net Income
3,388
Net Margin
32.9%
EPS (Basic)
$1.62
EPS (Diluted)
$1.54
EBITDA
3,622
EBITDA Margin
35.2%

2020

12/31/2020

Revenue
5,612
Cost of Revenue
3,079
Gross Profit
2,533
Gross Margin
45.1%
Operating Income
1,502
Operating Margin
26.8%
Net Income
1,689
Net Margin
30.1%
EPS (Basic)
$0.86
EPS (Diluted)
$0.80
EBITDA
1,771
EBITDA Margin
31.6%